Oragenics, Inc. (OGEN)
0.4109
+0.01
(+1.38%)
USD |
NYAM |
Oct 23, 16:00
0.4109
0.00 (0.00%)
After-Hours: 20:00
Oragenics Net Income (Quarterly) : -2.529M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -2.529M |
| March 31, 2026 | -2.201M |
| December 31, 2025 | -2.287M |
| September 30, 2025 | -3.067M |
| June 30, 2025 | -2.272M |
| March 31, 2025 | -2.217M |
| December 31, 2024 | -3.349M |
| September 30, 2024 | -2.463M |
| June 30, 2024 | -2.305M |
| March 31, 2024 | -2.451M |
| December 31, 2023 | -12.75M |
| September 30, 2023 | -2.013M |
| June 30, 2023 | -3.051M |
| March 31, 2023 | -2.845M |
| December 31, 2022 | -2.238M |
| September 30, 2022 | -3.870M |
| June 30, 2022 | -3.590M |
| March 31, 2022 | -4.591M |
| December 31, 2021 | -2.293M |
| September 30, 2021 | -4.384M |
| June 30, 2021 | -3.815M |
| March 31, 2021 | -5.220M |
| December 31, 2020 | -4.409M |
| September 30, 2020 | -4.497M |
| June 30, 2020 | -12.34M |
| Date | Value |
|---|---|
| March 31, 2020 | -5.188M |
| December 31, 2019 | -3.597M |
| September 30, 2019 | -3.836M |
| June 30, 2019 | -4.806M |
| March 31, 2019 | -3.326M |
| December 31, 2018 | -2.756M |
| September 30, 2018 | -2.758M |
| June 30, 2018 | -2.281M |
| March 31, 2018 | -2.119M |
| December 31, 2017 | -1.461M |
| September 30, 2017 | -2.067M |
| June 30, 2017 | -1.221M |
| March 31, 2017 | -1.983M |
| December 31, 2016 | -2.684M |
| September 30, 2016 | -2.006M |
| June 30, 2016 | -1.734M |
| March 31, 2016 | -2.074M |
| December 31, 2015 | -2.219M |
| September 30, 2015 | -1.864M |
| June 30, 2015 | -6.336M |
| March 31, 2015 | -1.293M |
| December 31, 2014 | -1.224M |
| September 30, 2014 | -1.030M |
| June 30, 2014 | -1.896M |
| March 31, 2014 | -1.641M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 2.529M |
| EPS Diluted (Quarterly) | -0.571 |
| Enterprise Value | -2.036M |
| Earnings Yield | -871.9% |
| Normalized Earnings Yield | -871.94 |